In this question and answer (Q&A) special report, a dozen IRB administrators, directors, chairs, and other leaders from across the United States were asked about their facilities’ experiences during the COVID-19 pandemic’s early weeks. The leaders responded candidly about their toughest challenges, best new tactics, and how they supported their human research protection community
- Gretchen L. J. Anding, MA, assistant director, UW-Madison Health Sciences IRBs Office, University of Wisconsin
- Cecilia Brooke Cholka, MA, CIP, IRB specialist, University of Nevada, Reno
- Francis J. DiMario, Jr., MD, MA, CIP, professor, pediatrics and neurology, The University of Connecticut; associate chair, academic affairs, department pediatrics; medical director, human research protection program (HRPP); chair of IRB, Connecticut Children’s Medical Center
- Teresa Doksum, PhD, MPH, senior director of quality and research ethics, Abt Associates, Cambridge, MA
- Harry McGee, MPH, SIRB chair, Michigan State University
- Brian Moore, MS, CIP, director, HRPP/IRB, Wake Forest School of Medicine, Clinical Translational Science Institute, Winston-Salem, NC
- Jon Newlin, CIP, assistant director, HRPP, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
- Linda Reuter, CIP, director, BRANY IRB, Biomedical Research Alliance of New York, Lake Success, NY
- Lisa Rigtrup, operations manager, IRB, University of Utah
- Catherine Rogers, post-approval team manager and senior IRB analyst, UW-Madison Health Sciences IRBs Office
- William Smith, JD, IRB director, Nova Southeastern University, Davie, FL
- Megan Williams, MPA, CIP, director of research administration, academic affairs, Salem State University, Salem, MA
